Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 972–973 | Cite as

ASO Author Reflections: We Can Stomach It: Personalizing Medicine with EGD-Derived Gastric Cancer Organoids

  • Miranda Lin
  • Joseph KimEmail author
ASO Author Reflections



The authors have no conflicts of interest to disclose.


  1. 1.
    Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med. 2017;177:1569–75.CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Gillet JP, Varma S, Gottesman MM. The clinical relevance of cancer cell lines. J Natl Cancer Inst. 2013;105:452–8.CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4:998–1013.CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Gao M, Lin M, Rao M, et al. Development of patient-derived gastric cancer organoids from endoscopic biopsies and surgical tissues. Ann Surg Oncol. 2018;25:2767–75.CrossRefGoogle Scholar
  5. 5.
    Merker SR, Weitz J, Stange DE. Gastrointestinal organoids: how they gut it out. Dev Biol. 2016;420:239–50.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Department of Surgery, Division of Surgical OncologyUniversity of Kentucky and Markey Cancer CenterLexingtonUSA

Personalised recommendations